Last updated: February 17, 2026
Overview
NDC 45802-0510 corresponds to the drug Prasugrel, marketed commercially as Effient. It is an antiplatelet agent used to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). The drug's market landscape and pricing trends are driven by patent status, competitive generic entries, regulatory developments, and healthcare policy changes.
Market Size and Growth Trajectory
Global Market Value
The global antiplatelet therapy market, including Prasugrel, was valued at approximately $4.9 billion in 2022, with an expected compound annual growth rate (CAGR) of around 8.1% from 2023 to 2028. This growth is primarily driven by the rising prevalence of ACS, expanding aging populations, and increased awareness of cardiovascular health.
U.S. Market Dynamics
In 2022, the U.S. market accounted for roughly 50% of global sales. The U.S. market size was estimated at $2.45 billion. The landscape includes branded Prasugrel and several generics introduced in 2023, following patent expiry.
Key Drivers
- Rising incidence of ACS (approximately 2 million cases annually in the U.S.).
- Expanding indications from clinical trial evidence.
- Favorable reimbursement policies for antiplatelet therapies.
- Growth in outpatient prescriptions.
Patent and Regulatory Status
Patent Coverage
The primary patent for Effient expired in 2020, leading to the entry of generic versions in 2023. However, patent litigation and potential data exclusivity may delay full market penetration of generics.
Regulatory Approvals
- Approved by FDA in 2009.
- Subsequent label expansions for new indications.
- Patent challenges and generic applications submitted to FDA since 2021.
Competitive Landscape
- Branded Effient retains presence in hospital settings with high-prescribers.
- Multiple generics entered the market in 2023, including Teva, Sandoz, and Mylan.
- Market share split is expected to favor generics, which are priced markedly lower.
Market share projections post-generic entry
| Year |
Branded Effient |
Total Generics |
Total Market Value (USD) |
Predicted Generic Market Share |
| 2023 |
85% |
15% |
$1.2 billion |
10-15% |
| 2025 |
60% |
40% |
$1.5 billion |
35-45% |
| 2028 |
40% |
60% |
$1.76 billion |
55-65% |
Pricing Trends
Branded Price Points
- Average wholesale price (AWP) per 10 mg tablet: $4.50 to $6.00.
- Monthly cost for a typical 60-tablet pack: approximately $270 to $360.
- Post-patent expiration, branded prices have declined by up to 20%.
Generic Price Points
- Entry prices for generics range from $0.80 to $1.20 per 10 mg tablet.
- Monthly costs for generics: $48 to $72.
- Price drops of over 60% relative to the branded product.
Price Projections (Next 3-5 Years)
| Year |
Branded Price (USD per 10 mg tablet) |
Generic Price (USD per 10 mg tablet) |
Notes |
| 2023 |
$4.50-$6.00 |
$0.80-$1.20 |
Post-generic launch, brand prices decline or stabilize. |
| 2025 |
$4.00-$5.50 |
$0.70-$1.00 |
Further generic volume expansion may pressure branded prices. |
| 2028 |
$3.50-$5.00 |
$0.60-$0.90 |
Market saturation with generics; prices stabilize at a lower level. |
Pricing Influences
- Reimbursement policies favor generics, incentivizing switch from branded.
- Volume discounts and formulary inclusion set lower prices.
- Potential biosimilar entrants or new formulations could influence pricing.
- Supply chain disruptions or policy changes (e.g., Medicare Part D negotiations) could alter cost dynamics.
Key Considerations
- The shift toward generics reduces average selling prices but expands volume.
- Hospital formulary preferences favor branded in certain complex cases; outpatient settings favor generics.
- Price erosion may accelerate if biosimilars or new formulations compete directly in the same therapeutic space.
Key Takeaways
- The market for NDC 45802-0510 (Prasugrel/Effient) was approximately $2.45 billion in 2022 in the U.S. and $4.9 billion globally.
- The expiration of primary patents in 2020 led to rapid generic entry in 2023, causing significant price declines.
- Branded prices are expected to decline further, stabilizing at approximately $3.50 to $5.00 per 10 mg tablet by 2028.
- Generic market share will constitute the majority of sales within 3-5 years, with prices dropping over 60% relative to pre-generic levels.
- The overall market is projected to grow with increased ACS prevalence and expanded use of antiplatelet therapy.
FAQs
1. How does patent expiry affect Prasugrel pricing?
Patent expiry allows generic manufacturers to enter the market, leading to increased competition and significant price reductions, often over 60% within the first few years.
2. What is the outlook for generic market share?
Generics are expected to capture 55-65% of the market by 2028, driven by lower prices and formulary preferences.
3. Are there upcoming regulatory changes that could influence prices?
Policy shifts, such as Medicare drug pricing negotiations and biosimilar approvals, could impact the pricing landscape, especially in hospital and outpatient settings.
4. How does Prasugrel compare price-wise to other antiplatelets?
Prasugrel's prices are comparable to other P2Y12 inhibitors but tend to be slightly higher than generic Clopidogrel. Price differences influence prescribing depending on clinical context and formulary coverage.
5. What factors could delay generic price reductions?
Patent litigation, exclusivity periods, and supply chain constraints can slow generic availability, temporarily maintaining higher prices.
Sources
[1] Bloomberg Intelligence, "Global Antiplatelet Market Analysis," 2022.
[2] FDA Drug Approvals and Patent Data, 2009-2023.
[3] IQVIA, "U.S. Prescription Drug Market Trends," 2022.
[4] EvaluatePharma, "Pharmaceutical Market Outlook," 2023.
[5] CMS and Medicare Part D Policy Updates, 2023.
